论文部分内容阅读
【目的】观察通冠胶囊对急性冠脉综合征(ACS)患者超敏C反应蛋白(hs-CRP)水平的影响。【方法】将ACS患者54例随机分为治疗组26例和对照组28例。2组给予一致的冠心病标准治疗和并发症处理,对照组加用安慰剂,治疗组加用通冠胶囊,疗程均为1个月。比较2组患者治疗前后的症状量化评分,并分别在入院时、治疗第7天和1个月后观察患者hs-CRP水平的变化。【结果】治疗后2组ACS患者症状量化评分有不同程度地改善(与治疗前比较,P<0.05或P<0.01),其中治疗组在改善患者胸闷痛程度、发作频率、持续时间和气短、疲乏、心悸等方面优于对照组(P<0.05或P<0.01)。治疗第7天和1个月后对照组患者的hs-CRP水平均无明显变化(与入院时比较,P>0.05),而治疗组患者的hs-CRP水平均下降(与入院时比较,P<0.05),尤其在治疗1个月后下降更为明显(与治疗第7天比较,P<0.05)。治疗后2组比较,治疗组的hs-CRP水平下降程度均优于对照组(P<0.05)。【结论】通冠胶囊可显著改善ACS患者的症状,并能降低ACS患者的hs-CRP水平。
【Objective】 To observe the effect of Tongguan Capsule on the level of hs-CRP in patients with acute coronary syndrome (ACS). 【Methods】 54 patients with ACS were randomly divided into treatment group (n = 26) and control group (n = 28). The two groups were given the same standard treatment of coronary heart disease and complications, the control group plus placebo, the treatment group plus Tongguan capsule, the course of treatment was 1 month. The scores of symptoms before and after treatment were compared between the two groups, and the change of hs-CRP level was observed on admission, on the 7th day and 1 month after treatment respectively. [Results] After treatment, the symptom scores of ACS patients in two groups improved to some extent (compared with before treatment, P <0.05 or P <0.01), and the treatment group was significantly improved in the degree of chest pain, frequency of attack, duration and shortness of breath, Fatigue, palpitations, etc. than the control group (P <0.05 or P <0.01). There was no significant difference in hs-CRP levels between the control group and the seventh day and the first month after treatment (P> 0.05), while the hs-CRP level in the treatment group decreased (P <0.05), especially after 1 month of treatment, the decrease was more significant (P <0.05 compared with the 7th day of treatment). After treatment, the levels of hs-CRP in treatment group were significantly lower than those in control group (P <0.05). 【Conclusion】 Tongguan capsule can significantly improve the symptoms of ACS patients and reduce the hs-CRP level in ACS patients.